CSPC Ouyi Pharmaceutical Co., Ltd.
Quick facts
Phase 3 pipeline
- ABCD
ABCD is an investigational drug in phase 3 development by CSPC Ouyi Pharmaceutical Co., Ltd., but its specific mechanism of action is not publicly disclosed. - pregabalin sustained-release tablets
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing neurotransmitter release. - SYHX1901
SYHX1901 is a small molecule drug that targets the molecular target. - SYHX2011 · Diabetes
SYHX2011 is a small molecule drug that targets the SGLT2 receptor.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- CSPC Ouyi Pharmaceutical Co., Ltd. portfolio CI brief
- CSPC Ouyi Pharmaceutical Co., Ltd. pipeline updates RSS
Frequently asked questions about CSPC Ouyi Pharmaceutical Co., Ltd.
What is CSPC Ouyi Pharmaceutical Co., Ltd.'s pipeline?
CSPC Ouyi Pharmaceutical Co., Ltd. has 4 drugs in Phase 3, 0 in Phase 2, 4 in Phase 1. Late-stage candidates include ABCD, pregabalin sustained-release tablets, SYHX1901, SYHX2011.
Related
- Sector hub: All tracked pharma companies